

PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

30 November 2012

FACTS

Portfolio Value \$39.60 mn Fund commenced 10 November 2003 Minimum investment A\$20,000 or NZ\$25,000 A\$200 or NZ\$250 per mth/qtr Regular Investment Plan (min.)

Income distribution date Annual, 30 June Sydney Business Day Unit valuation

Unit prices App 1.1844 Red 1.1784

FEES

Nil Entry fee Exit fee Nil

Management Expense Ratio/ 1.54% per annum

Indirect Cost Ratio (MER/ICR) (inclusive of investment & administration costs)

Brokerage paid 0.5% total Buy/sell spread

PERFORMANCE 1		
	FUND %	MSCI %
1 month	0.90	0.16
3 months	5.83	3.19
6 months	9.50	6.38
1 year	19.71	19.13
2 years (compound pa)	13.61	11.01
3 years (compound pa)	11.50	5.59
5 years (compound pa)	4.44	0.22
7 years (compound pa)	5.27	0.47
Since inception (compound pa)	4.51	2.46

INVESTED POSITION	L ³		
	LONG %	NET %	CURRENCY %
Australia	0.8	0.8	15.2
Belgium	3.9	3.9	
Brazil	1.1	1.1	1.1
China (Listed ex PRC)	1.4	1.4	
Denmark	1.6	1.6	1.3
France	5.5	5.5	
Germany	6.7	6.7	
Italy	3.2	3.2	
Japan	4.1	4.1	4.8
Sweden	4.0	4.0	4.0
Switzerland	8.8	8.8	4.9
UK	2.3	2.3	2.3
US	26.5	23.8	29.4
Total	69.9	67.2	
Canada			3.2
Euro			21.8
Hong Kong			1.6
Korea			2.5
Norway			2.4
Singapore			5.5
Cash & Accruals	30.1	32.8	
Total	100.0	100.0	100.0
Long - 46 stocks Short - 3	stocks		•

1. Investment returns are calculated using the Fund's unit price and represent the combined income capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The returns shown are historical and no warranty can be given for future performance. You should be that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns be negative (particularly in the short-term).

2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund inception relative to the MSCI All Country World Health Care Net Index in A\$.

The investment returns are calculated using the Fund's unit price.

They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.

make-up of the Index. The Index is provided as a reference only.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives. The "Net %" represents the exposure of physical holdings and short derivatives. The "Currency %" represents the currency exposure for the Fund's Portfolio, taking into

account currency hedging.

4. Top Ten positions shows the Fund's top long share exposure positions. Long derivative exposures are included, however, short derivative exposures are not.

PERFORMANCE C	iraph ²			
\$30,000 7				
		Platinum Inf	t'l Health Ca	
\$27,000 -				49.3%
		M.	••	
\$24,000				/" <i>[</i>
^	\	" " (
\$21,000	$\mathbf{W} \mathbf{J}$	V	M/h	
	M [Mag	AGW HILL	V V
\$18,000	' V	MSCI	AC World H	eaith Care 24.8%
	•			
\$15,000				
2003	2005	2007	2009	2011
Source: Factset and Pla	tinum			

TOP TEN POSITIONS	4		
<u>STOCK</u>	COUNTRY	<u>INDUSTRY</u>	<u>%</u>
Sanofi SA	France	Pharmaceuticals	3.4
Sartorius AG	Germany	Health Equip & Services	3.2
Novartis AG	Switzerland	Pharmaceuticals	2.5
Qiagen NV	Germany	Health Equip & Services	2.5
Gilead Sciences Inc	United States	Biotechnology	2.5
Teva Pharmaceuticals	United States	Pharmaceuticals	2.4
Thombogenics NV	Belgium	Biotechnology	2.4
Pfizer Inc	United States	Pharmaceuticals	2.4
Roche Holding AG	Switzerland	Pharmaceuticals	2.4
Ipsen SA	France	Pharmaceuticals	2.1

INDUSTRY BREAKDOWN 3			
SECTOR	LONG %	NET %	
Pharmaceuticals	37.1	36.6	
Health Equipment & Services	13.1	12.3	
Biotechnology	11.9	11.9	
Healthcare Providers	3.8	3.8	
Misc Manufacturing	2.6	2.6	
Electrical Equipment	1.4	1.4	
Equity Funds		(1.4)	

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management (Platinum) is the responsible entity and issuer of units in the Platinum Int'l Health Care Fund (the Fund). The Platinum Trust Product Disclosure Statement No.8 and Supplementary PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS 700 Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via Invest@platinum.com.au

Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the PDS when deciding to acquire, or continue to hold, units in the Fund.

DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment of capital, payment of income or the Fund's performance. Platinum is a member of the Platinum Group of companies.